EverImmune Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
EverImmune General Information
Description
Developer of live biotherapeutic products designed to improve the efficacy of immunotherapy in cancer patients. The company specializes in developing technology that utilizes gut microbiota to restore responsiveness to immune checkpoint inhibitors, employing theragnostic approaches that combine diagnostic and therapeutic technologies, enabling cancer patients to potentially improve treatment outcomes and address primary resistance issues.
Contact Information
Website
www.everimmune.comCorporate Office
- 39 Rue Camille Desmoulins
- 94800 Villejuif
- France
Corporate Office
- 39 Rue Camille Desmoulins
- 94800 Villejuif
- France
EverImmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 4. Debt - General | 19-Sep-2023 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2022 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 30-Nov-2021 | $5.71M | $5.71M | Completed | Pre-Clinical Trials | |
| 1. Spin-Off | 26-May-2016 | Completed | Pre-Clinical Trials |
EverImmune Comparisons
Industry
Financing
Details
EverImmune Competitors (8)
One of EverImmune’s 8 competitors is Bloom Science, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bloom Science | Venture Capital-Backed | San Diego, CA | ||||
| GlycosBio | Venture Capital-Backed | Houston, TX | ||||
| AbCellera Biologics | Formerly VC-backed | Vancouver, Canada | ||||
| Alveolus Bio | Venture Capital-Backed | Birmingham, AL | ||||
| LifeMine | Venture Capital-Backed | Cambridge, MA |
EverImmune Patents
EverImmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4794707-A1 | Bacterial composition comprising akkermansia species, for improving the response to car t-cell therapy | Pending | 19-Oct-2023 | ||
| AU-2022297690-A1 | Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy | Pending | 21-Jun-2021 | ||
| CA-3223488-A1 | Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy | Pending | 21-Jun-2021 | ||
| EP-4359795-A1 | Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy | Active | 21-Jun-2021 | ||
| EP-4359795-B1 | Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy | Active | 21-Jun-2021 | G01N33/575 |
EverImmune Signals
EverImmune Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Matwin | Accelerator/Incubator | |||
| Gustave Roussy | Corporation |
EverImmune FAQs
-
When was EverImmune founded?
EverImmune was founded in 2016.
-
Where is EverImmune headquartered?
EverImmune is headquartered in Villejuif, France.
-
What is the size of EverImmune?
EverImmune has 4 total employees.
-
What industry is EverImmune in?
EverImmune’s primary industry is Drug Discovery.
-
Is EverImmune a private or public company?
EverImmune is a Private company.
-
What is EverImmune’s current revenue?
The current revenue for EverImmune is .
-
How much funding has EverImmune raised over time?
EverImmune has raised $9.5M.
-
Who are EverImmune’s investors?
Matwin and Gustave Roussy have invested in EverImmune.
-
Who are EverImmune’s competitors?
Bloom Science, GlycosBio, AbCellera Biologics, Alveolus Bio, and LifeMine are some of the 8 competitors of EverImmune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process